Studie av Lumateperone som tilläggsterapi vid behandling av patienter med allvarlig depressiv sjukdom
En randomiserad, dubbelblind, placebokontrollerad multicenterstudie för att bedöma effektiviteten och säkerheten av Lumateperone som tilläggsterapi vid behandling av patienter med allvarlig depressiv sjukdom
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Fas 3
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studieorter
-
-
-
Cherven Bryag, Bulgarien, 5980
- Rekrytering
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali, Bulgarien, 6600
- Rekrytering
- Medical Center Lifemed
-
Pleven, Bulgarien, 5800
- Rekrytering
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgarien, 4004
- Rekrytering
- Medical Center Mentalcare OOD
-
Sofia, Bulgarien, 1680
- Rekrytering
- Medical Center Intermedica, OOD
-
Sofia, Bulgarien, 1510
- Rekrytering
- Medical Center Hera EOOD
-
Sofia, Bulgarien, 1202
- Rekrytering
- MHC - Sofia, EOOD
-
Sofia, Bulgarien, 1431
- Avslutad
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora, Bulgarien, 6003
- Avslutad
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna, Bulgarien, 9020
- Rekrytering
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Douai, Frankrike, 59500
- Rekrytering
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes, Frankrike, 44093
- Rekrytering
- CHU de Nantes hotel Dieu
-
Nîmes, Frankrike, 30029
- Rekrytering
- Hopital Caremeau
-
Paris, Frankrike, 75012
- Rekrytering
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers, Frankrike, 86021
- Rekrytering
- CH Henri Laborit
-
-
-
-
Alabama
-
Huntsville, Alabama, Förenta staterna, 35801
- Rekrytering
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera, California, Förenta staterna, 90660
- Rekrytering
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington, Connecticut, Förenta staterna, 06030
- Rekrytering
- University of Connecticut Health Center
-
-
Florida
-
Clermont, Florida, Förenta staterna, 34711
- Avslutad
- Vertex Clinical Research
-
Hialeah, Florida, Förenta staterna, 33012
- Upphängd
- New Life Medical Research Center, Inc.
-
Miami, Florida, Förenta staterna, 33122
- Rekrytering
- Premier Clinical Research Institute
-
Miami, Florida, Förenta staterna, 33137
- Rekrytering
- Miami Jewish Health System
-
Tampa, Florida, Förenta staterna, 33629
- Rekrytering
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Rekrytering
- The Emory Clinic
-
Decatur, Georgia, Förenta staterna, 30030
- Rekrytering
- CenExeli Research LLC
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Avslutad
- University of Kansas Medical Center Research Institute
-
Overland Park, Kansas, Förenta staterna, 66210
- Rekrytering
- Collective Medical Research
-
-
Massachusetts
-
Methuen, Massachusetts, Förenta staterna, 01844
- Avslutad
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon, Missouri, Förenta staterna, 63368
- Rekrytering
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Förenta staterna, 08755
- Rekrytering
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Förenta staterna, 11235
- Rekrytering
- SPRI Clinical Trials, LLC
-
New York, New York, Förenta staterna, 10036
- Rekrytering
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake, Ohio, Förenta staterna, 44012
- Rekrytering
- Quest Therapeutics of Avon Lake
-
Cincinnati, Ohio, Förenta staterna, 45219
- Rekrytering
- University of Cincinnati Medical Center
-
Columbus, Ohio, Förenta staterna, 43210
- Rekrytering
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston, Texas, Förenta staterna, 77081
- Rekrytering
- DM Clinical Research
-
Mansfield, Texas, Förenta staterna, 76063
- Avslutad
- Hawkins Psychiatry, PC
-
Richardson, Texas, Förenta staterna, 75080
- Rekrytering
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, Förenta staterna, 98007
- Rekrytering
- Northwest Clinical Research Center
-
-
-
-
-
Ahmedabad, Indien, 380008
- Upphängd
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad, Indien, 380009
- Upphängd
- Sushrusha Navneet Memorial Hospital
-
Ajmer, Indien, 305001
- Upphängd
- J L N Medical College and Attached Hospitals
-
Bikaner, Indien, 334001
- Rekrytering
- S P Medical College And Associated Group of Hospitals
-
Bārāmati, Indien, 413102
- Rekrytering
- Baramati Hospital
-
Chandigarh, Indien, 160012
- Rekrytering
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati, Indien, 781032
- Avslutad
- Gauhati Medical College and Hospital
-
Kolhāpur, Indien, 416001
- Rekrytering
- Swastik Hospital
-
Nagpur, Indien, 440001
- Rekrytering
- KIMS-Kingsway Hospitals
-
Palsāna, Indien, 394315
- Rekrytering
- Divyam Hospital
-
Pune, Indien, 411011
- Rekrytering
- Shree Samarth Hospital
-
Rajkot, Indien, 360001
- Avslutad
- Nagecha Hospital
-
Wardha, Indien, 442004
- Upphängd
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Kaunas, Litauen, LT-44279
- Avslutad
- Romuvos Klinika, JSC
-
Ziegzdriai, Litauen, 53136
- Avslutad
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
-
Belgrade, Serbien, 11000
- Rekrytering
- University Clinical Center of Serbia
-
Belgrade, Serbien, 11000
- Rekrytering
- Institute of Mental Health Serbia
-
Belgrade, Serbien, 11000
- Rekrytering
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin, Serbien, 26220
- Rekrytering
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac, Serbien, 34000
- Rekrytering
- University Clinical Center Kragujevac
-
Kragujevac, Serbien, 34000
- Rekrytering
- University Clinical Center Kragujevac 1
-
Niš, Serbien, 18000
- Rekrytering
- University Clinical Center NIS 1
-
Niš, Serbien, 18000
- Rekrytering
- University Clinical Center NIS
-
Novi Kneževac, Serbien, 23330
- Rekrytering
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Barcelona, Spanien, 08036
- Rekrytering
- Hosp. Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Rekrytering
- Hosp Univ Vall D Hebron
-
Madrid, Spanien, 28034
- Avslutad
- Hosp. Univ. Ramon Y Cajal
-
Sabadell, Spanien, 08208
- Rekrytering
- Hosp.Univ.Parc Tauli
-
Zamora, Spanien, 49021
- Rekrytering
- Hosp. Prov. de Zamora
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
|
Matching capsules administered orally, once daily |
|
Experimentell: Lumateperon 42 mg
|
Lumateperone 42 mg capsules administered orally, once daily |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
Tidsram: Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinical Global Impression Scale-Severity
Tidsram: Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- ITI-007-505
- ITI-007-505 (Annan identifierare: Janssen Research & Development, LLC)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .